RxDoctor Payments DataLook up a doctor →

Frank Weinholt, MD

Psychiatry · West Monroe, LANPI 1326126442

Payments from drug & device makers

$29,217in general payments, 2019–2025

Across 734 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$16K
  • Acadia Pharmaceuticals Inc$4K
  • Neurocrine Biosciences, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • AbbVie$929
  • plus $4K from 14 others

What the payments were for

  • Speaking & faculty fees$14,40049%
  • Travel & lodging$8333%
  • Food & beverage$13,87447%
  • Education$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,217 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$22,732
Medicare patients
72
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate45$225,035
VraylarCariprazine Hcl26$52,498
CaplytaLumateperone Tosylate31$47,847
RexultiBrexpiprazole27$41,061
NuedextaDextromethorphan Hbr/Quinidine23$27,866
TrintellixVortioxetine Hydrobromide30$16,567
Rivastigmine108$15,965
FetzimaLevomilnacipran Hcl12$11,350
EliquisApixaban17$8,978
Aripiprazole39$7,559
Memantine Hcl119$4,757
Ziprasidone Hcl47$3,649
Pimozide67$2,923
Venlafaxine Hcl ErVenlafaxine Hcl52$2,738
Lamotrigine210$2,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$3,805$225,03545 claims
AbbVieVraylar, Fetzima$929$63,84838 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,294$47,84731 claims
Otsuka America Pharmaceutical, Inc.Rexulti$840$41,06127 claims
Avanir Pharmaceuticals, Inc.Nuedexta$16,073$27,86623 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$214$16,56730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in West Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →